4DMEDICAL Ltd Wins TGA Approval for Lung Imaging Tool in Australia

4DMedical (ASX:4DX) has secured TGA approval for its CT:VQ™ lung imaging solution, unlocking commercial deployment across Australia's world-leading CT scanner network and opening a Medicare reimbursement pathway.

By Josua Ferreira -

Key Takeaways

  • 4DMedical has received TGA approval for CT:VQ™ and inclusion in the Australian Register of Therapeutic Goods, clearing the path for commercial deployment across Australia for the first time.
  • Australia ranks second globally for CT scanner density at more than 74 scanners per million people, giving CT:VQ™ an immediately accessible infrastructure base that requires no new capital investment from healthcare providers.
  • CT:VQ™ now holds regulatory approval across six jurisdictions — the US, EU, UK, Canada, New Zealand and Australia — with US deployment already active at Stanford, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine and University of Miami.
  • Peer-reviewed clinical data published in the world's leading respiratory medicine journal shows CT:VQ-guided patient selection achieving a 76% surgical response rate versus 46% under current methods, forming the evidentiary backbone for the forthcoming MSAC Medicare reimbursement submission.
  • 4DMedical operates a SaaS delivery model and holds pharmaceutical imaging contracts with GSK and AstraZeneca, with management framing 2026 as a defining commercial year across both home and international markets.
This is a special feature video produced for our partner.

Breaking ASX Alerts Direct to Your Inbox

Join +20,000 subscribers receiving alerts.

Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.

About the Publisher